Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in IPF and SSc-ILD
2022-502828-42-00Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) comparing Vixarelimab with Placebo (2 arms). Primary endpoint: Absolute change from baseline to Week 52 in FVC (mL). Started Aug 2023; status: completed.
02
Drugs
vixarelimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2022-502828-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502828-42-00.